Stock listing
NYSE American:ATNM Actinium Pharmaceuticals, Inc. (Delaware) Stock
Home listing (NYSE American) of Actinium Pharmaceuticals, Inc. (Delaware)
Follow Actinium Pharmaceuticals, Inc. (Delaware) into a list and get an email when it puts out news.
Share price · AMEX:ATNM
$1.05 USD -0.02 (-1.9%)
Close on Nov 20, 2026
- Day range
- $1.00 – $1.10 USDNov 20, 2026
- Volume
- 280,659 sharesNov 20, 2026
- Market cap
- $33.01M USDAt the close on Nov 20, 2026 · price × 31.44M shares outstanding
- 52-week range
- $0.735 – $1.72 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $251,047 USDMedian day 115,250 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NYSE American:ATNM · Home | $1.05 USD | -0.02 (-1.9%) | 280,659 | $1.07 | $1.10 | $1.00 | $1.07 | Close on Nov 20, 2026 |
| Frankfurt:7AY1 | €0.948 EUR | -0.017 (-1.8%) | — | €0.948 | €0.948 | €0.948 | €0.965 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · AMEX:ATNM · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.05 | -0.02 | -1.9% | $1.07 | $1.10 | $1.00 | 280,659 | |
| $1.07 | -0.01 | -0.9% | $1.08 | $1.18 | $1.03 | 166,488 | |
| $1.08 | -0.27 | -20.0% | $1.33 | $1.34 | $1.08 | 326,840 | |
| $1.35 | -0.14 | -9.4% | $1.45 | $1.49 | $1.28 | 555,005 | |
| $1.49 | -0.15 | -9.1% | $1.64 | $1.685 | $1.465 | 347,947 | |
| $1.64 | +0.05 | +3.1% | $1.60 | $1.64 | $1.55 | 180,600 | |
| $1.59 | 0.00 | 0.0% | $1.61 | $1.67 | $1.53 | 348,100 | |
| $1.59 | +0.02 | +1.3% | $1.52 | $1.65 | $1.49 | 115,500 | |
| $1.57 | +0.03 | +1.9% | $1.55 | $1.61 | $1.50 | 176,400 | |
| $1.54 | +0.11 | +7.7% | $1.44 | $1.62 | $1.43 | 467,400 | |
| $1.43 | +0.13 | +10.0% | $1.28 | $1.43 | $1.28 | 89,200 | |
| $1.30 | -0.11 | -7.8% | $1.38 | $1.39 | $1.30 | 213,000 | |
| $1.41 | +0.01 | +0.7% | $1.42 | $1.45 | $1.36 | 104,300 | |
| $1.40 | -0.03 | -2.1% | $1.40 | $1.46 | $1.40 | 75,800 | |
| $1.43 | -0.05 | -3.4% | $1.48 | $1.53 | $1.41 | 104,600 | |
| $1.48 | -0.05 | -3.3% | $1.51 | $1.535 | $1.45 | 157,700 | |
| $1.53 | +0.15 | +10.9% | $1.38 | $1.56 | $1.38 | 181,700 | |
| $1.38 | -0.04 | -2.8% | $1.40 | $1.42 | $1.35 | 56,600 | |
| $1.42 | +0.02 | +1.4% | $1.40 | $1.55 | $1.40 | 107,000 | |
| $1.40 | -0.12 | -7.9% | $1.50 | $1.53 | $1.36 | 205,800 | |
| $1.52 | -0.08 | -5.0% | $1.60 | $1.63 | $1.469 | 242,000 | |
| $1.60 | +0.22 | +15.9% | $1.33 | $1.66 | $1.33 | 827,800 | |
| $1.38 | -0.02 | -1.4% | $1.38 | $1.409 | $1.33 | 357,900 | |
| $1.40 | +0.08 | +6.1% | $1.36 | $1.50 | $1.35 | 900,300 | |
| $1.32 | +0.19 | +16.8% | $1.14 | $1.40 | $1.13 | 657,200 | |
| $1.13 | +0.07 | +6.6% | $1.09 | $1.15 | $1.05 | 174,400 | |
| $1.06 | +0.085 | +8.7% | $0.95 | $1.07 | $0.95 | 143,200 | |
| $0.975 | -0.025 | -2.5% | $0.99 | $1.023 | $0.952 | 84,600 | |
| $1.00 | -0.06 | -5.7% | $1.07 | $1.07 | $0.996 | 87,900 | |
| $1.06 | -0.04 | -3.6% | $1.09 | $1.09 | $1.029 | 97,600 | |
| $1.10 | +0.02 | +1.9% | $1.09 | $1.12 | $1.07 | 105,800 | |
| $1.08 | +0.01 | +0.9% | $1.09 | $1.10 | $1.06 | 104,900 | |
| $1.07 | -0.04 | -3.6% | $1.08 | $1.12 | $1.05 | 100,100 | |
| $1.11 | -0.09 | -7.5% | $1.20 | $1.22 | $1.02 | 439,600 | |
| $1.20 | +0.03 | +2.6% | $1.16 | $1.24 | $1.16 | 115,000 | |
| $1.17 | +0.02 | +1.7% | $1.15 | $1.19 | $1.12 | 81,800 | |
| $1.15 | +0.03 | +2.7% | $1.11 | $1.15 | $1.11 | 90,800 | |
| $1.12 | -0.02 | -1.8% | $1.14 | $1.20 | $1.10 | 95,100 | |
| $1.14 | -0.04 | -3.4% | $1.17 | $1.17 | $1.14 | 62,022 | |
| $1.18 | -0.02 | -1.7% | $1.18 | $1.20 | $1.17 | 75,373 | |
| $1.20 | +0.01 | +0.8% | $1.19 | $1.205 | $1.18 | 28,400 | |
| $1.19 | +0.01 | +0.8% | $1.19 | $1.25 | $1.18 | 84,800 | |
| $1.18 | +0.01 | +0.9% | $1.17 | $1.21 | $1.16 | 130,400 | |
| $1.17 | -0.03 | -2.5% | $1.18 | $1.22 | $1.17 | 54,500 | |
| $1.20 | -0.02 | -1.6% | $1.24 | $1.24 | $1.166 | 99,400 | |
| $1.22 | +0.03 | +2.5% | $1.18 | $1.23 | $1.18 | 146,200 | |
| $1.19 | -0.05 | -4.0% | $1.26 | $1.26 | $1.18 | 56,700 | |
| $1.24 | -0.01 | -0.8% | $1.26 | $1.275 | $1.24 | 59,800 | |
| $1.25 | -0.03 | -2.3% | $1.28 | $1.32 | $1.25 | 96,100 | |
| $1.28 | -0.12 | -8.6% | $1.41 | $1.418 | $1.25 | 301,500 | |
| $1.40 | +0.09 | +6.9% | $1.31 | $1.42 | $1.285 | 238,200 | |
| $1.31 | +0.08 | +6.5% | $1.25 | $1.34 | $1.23 | 226,800 | |
| $1.23 | 0.00 | 0.0% | $1.24 | $1.305 | $1.22 | 366,600 | |
| $1.23 | +0.20 | +19.4% | $1.06 | $1.25 | $1.06 | 574,100 | |
| $1.03 | -0.02 | -1.9% | $1.05 | $1.055 | $1.02 | 54,000 | |
| $1.05 | +0.05 | +5.0% | $1.02 | $1.06 | $1.01 | 72,000 | |
| $1.00 | +0.004 | +0.4% | $1.00 | $1.04 | $1.00 | 74,900 | |
| $0.996 | -0.024 | -2.4% | $1.01 | $1.022 | $0.996 | 30,100 | |
| $1.02 | +0.01 | +1.0% | $1.03 | $1.03 | $1.01 | 34,800 | |
| $1.01 | +0.01 | +1.0% | $1.00 | $1.028 | $0.97 | 111,600 | |
| $1.00 | -0.01 | -1.0% | $1.01 | $1.05 | $1.00 | 92,900 | |
| $1.01 | -0.07 | -6.5% | $1.08 | $1.08 | $1.01 | 145,100 | |
| $1.08 | +0.03 | +2.9% | $1.07 | $1.10 | $1.05 | 159,003 | |
| $1.05 | -0.05 | -4.5% | $1.10 | $1.10 | $1.04 | 64,454 | |
| $1.10 | -0.02 | -1.8% | $1.13 | $1.14 | $1.10 | 143,800 | |
| $1.12 | -0.01 | -0.9% | $1.13 | $1.14 | $1.07 | 121,400 |
Splits
1 split · AMEX:ATNM · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-30 | Consolidation |
- Ticker
- NYSE American:ATNM
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NYSE American
- Currency
- USD
What changed lately
Latest news release · Nov 17, 2026
Actinium Pharmaceuticals Provides Third Quarter 2026 Corporate Update Highlighting ATNM-400 and Other Business Progress
Latest deck · November 2026
Actinium Pharmaceuticals — Investor Presentation (November 2026)
Investor deck · 36 slides
Latest news
Actinium Pharmaceuticals Provides Third Quarter 2026 Corporate Update Highlighting ATNM-400 and Other Business Progress
Nov 17, 2026
Closed $1.35 (-9.4%) on Nov 17, 2026
Actinium Pharmaceuticals to Host KOL Webinar on ATNM-400, a First-in-Class HER3-Targeted Alpha Radiotherapy
Nov 12, 2026
Closed $1.59 (0.0%) on Nov 12, 2026
Actinium Pharmaceuticals Announces Enrollment in the RADIANZ Imaging Clinical Trial Intended to Demonstrate the Pan-Cancer Potential of ATNM-400, A First-in-Class HER3-Targeting Radiotherapy
Nov 11, 2026
Closed $1.59 (+1.3%) on Nov 11, 2026
Actinium Pharmaceuticals Announces Formation of Scientific Advisory Board Featuring Leading Experts in Oncology and Radiopharmaceutical Development
Nov 9, 2026
Closed $1.54 (+7.7%) on Nov 9, 2026
Actinium Pharmaceuticals Announces Three ASH 2026 Abstracts Highlighting Iomab-ACT Clinical Results in CAR T-Cell Therapy and Sickle Cell Disease
Nov 4, 2026
Closed $1.41 (+0.7%) on Nov 4, 2026
Actinium Pharmaceuticals Announces ASH 2026 Abstract Highlighting Long-Term Results of Actimab-A in Combination with CLAG-M in Relapsed or Refractory AML
Nov 4, 2026
Closed $1.41 (+0.7%) on Nov 4, 2026
Actinium Pharmaceuticals Announces Acceptance of ATNM-400 Abstract for Presentation at SABCS 2026 Highlighting Activity Across Therapy-Resistant Breast Cancer Models
Nov 2, 2026
Closed $1.43 (-3.4%) on Nov 2, 2026
Actinium Pharmaceuticals Announces Inducement Grant to New Employee
Oct 30, 2026
Closed $1.43 (-3.4%) on Nov 2, 2026
Actinium Pharmaceuticals, Inc. (Delaware) on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 28 in the last 12 months · 39 in all · newest Nov 17, 2026 · oldest 2025
- Decks
- 24 decks · latest November 2026
Where Actinium Pharmaceuticals, Inc. (Delaware) is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NYSE American:ATNM · Home listing · This page | NYSE American | United States | USD |
| Lang & Schwarz:A2QA48 | Lang & Schwarz | Germany | EUR |
| gettex:7AY1 | gettex | Germany | EUR |
| LS Exchange:A2QA48 | LS Exchange | Germany | EUR |
| Tradegate:7AY1 | Tradegate | Germany | EUR |
| BOATS:ATNM | BOATS | United States | USD |
| Stuttgart:7AY1 | Stuttgart | Germany | EUR |
| Dusseldorf:7AY1 | Dusseldorf | Germany | EUR |
| Frankfurt:7AY1 | Frankfurt | Germany | EUR |
Valuation
Price/book 1.3× against a median of 1.2×: 7th lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $5.49M USD
- P/E
- 3.1×
- EV/sales
- No revenue
- EV/EBITDA
- 0.6×
- Price/book
- 1.3×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.1×
- Beta vs S&P 500
- 0.71
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Actinium Pharmaceuticals, Inc. (Delaware) · AMEX:ATNM | US$33.01M | US$5.49M | 3.1× | n/a | 0.6× | 1.3× | n/a | 0.1× | 0.71 |
| Cue Biopharma, Inc. · NASDAQ:CUE | US$34.69M | −US$23.25M | n/a | −0.7× | n/a | 0.9× | −580.0% | 0.0× | 2.35 |
| B&K Corporation Limited Class H · HKEX:2396 | US$33.15M | −US$47.10M | n/a | −602× | n/a | 0.4× | n/a | 0.0× | n/a |
| Veru Inc. · NASDAQ:VERU | US$33.08M | US$9.20M | n/a | n/a | n/a | 1.2× | n/a | 0.0× | 1.92 |
| Neurizon Therapeutics Limited · ASX:NUZ | US$32.76M | US$26.54M | n/a | 2.3× | n/a | 3.9× | −61.0% | 0.3× | n/a |
| CJ Bioscience. Inc. · KRX:311690 | US$32.52M | US$1.91M | n/a | 0.7× | n/a | 1.0× | −607.2% | 0.0× | n/a |
| Transcenta Holding Limited · HKEX:6628 | US$32.41M | US$52.52M | n/a | 12.4× | n/a | 0.4× | −569.5% | 0.3× | n/a |
| Enimmune Corporation · TPEX:6564 | US$31.74M | US$26.87M | n/a | 18.4× | n/a | 10.4× | −341.0% | 0.3× | n/a |
| Molecure SA · GPW:MOC | US$31.66M | US$29.60M | n/a | n/a | n/a | 1.3× | n/a | 0.0× | n/a |
| Sareum Holdings plc · LSE:SAR | US$31.03M | US$27.78M | n/a | n/a | n/a | 19.9× | n/a | 0.0× | n/a |
| Isofol Medical AB · OMXSTO:ISOFOL | US$31.03M | US$19.80M | n/a | n/a | n/a | 3.3× | n/a | 0.0× | n/a |
| Median of the others | US$32.46M | US$23.17M | 1.5× | 1.2× | −569.5% | 0.0× | 2.13 |
Forecasts
2 strong buy · 2 buy · 1 hold · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 4.00 USD · Analysts' mean
- EPS, year to Dec 2026
- 0.16 · 1 analyst
- Revenue, year to Dec 2026
- 26.25M · 4 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Sandesh Seth | Chief Executive Officer and Chairman of the Board |
| Matt David | Chief Financial Officer |
| Paul Diamond | Vice President, Legal and Intellectual Property Counsel |
| Ryan Chu | Vice President, Finance and Investor Relations |
| Gary Siegel | Vice President, Controller |
| Julie Gibson | Vice President, Portfolio and Clinical Operations |
| Monideepa Roy | Senior Vice President, Corporate Development – R&D |
| Sean Maenpaa | Senior Vice President, Business Development |
| Adeela Kamal | Chief Scientific Officer |
| Steffen Heeger | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Sandesh Seth | Chief Executive Officer and Chairman of the Board |
| Ajit Shetty | Director |
| C. David Nicholson | Lead Independent Director |
| Jeffrey W. Chell | Director |
| June Almenoff | Director |
| Richard l. Steinhart | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 16, 2026 · After close | −9.4% |
| Q2 2026 | Aug 7, 2026 | −2.2% |
| Q1 2026 | May 8, 2026 · After close | +2.3% |
| Q4 2025 | Mar 13, 2026 | −1.8% |
| Q3 2025 | Nov 14, 2025 · After close | +14.2% |
| Q2 2025 | Aug 8, 2025 · After close | −4.5% |
| Q1 2025 | May 9, 2025 · After close | +4.7% |
| Q4 2024 | Mar 27, 2025 · After close | −4.2% |
| Q3 2024 | Nov 14, 2024 · After close | −9.1% |
| Q2 2024 | Aug 5, 2024 · After close | +15.7% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | Apr 26, 2024 · After close | +7.4% |
| Q4 2023 | Mar 29, 2024 · After close | +9.3% |
| Q3 2023 | Nov 2, 2023 · Before open | −15.5% |
| Q2 2023 | Aug 14, 2023 · After close | +2.4% |
| Q1 2023 | May 15, 2023 · After close | −5.9% |
| Q4 2022 | Mar 31, 2023 · After close | −2.6% |
| Q3 2022 | Nov 14, 2022 · After close | −1.9% |
| Q2 2022 | Aug 12, 2022 · After close | +1.9% |
| Q1 2022 | May 13, 2022 · After close | −0.2% |
| Q4 2021 | Mar 25, 2022 · After close | −3.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Actinium Pharmaceuticals — Investor Presentation (November 2026) | Investor deck | 36 slides | November 2026 |
| Actinium Pharmaceuticals — Technical Presentation (October 2026) | Technical | 12 slides | Oct 19, 2026 |
| Actinium Pharmaceuticals — Investor Presentation (October 2026) | Investor deck | 26 slides | October 2026 |
| Actinium Pharmaceuticals — 4th Annual Targeted Radiotherapeutics Summit 2025 | Conference | 24 slides | Jul 30, 2025 |
| Actinium Pharmaceuticals — Technical Presentation (March 2025) | Technical | 43 slides | Mar 25, 2025 |
| Actinium Pharmaceuticals — Technical Presentation (May 2024) | Technical | 35 slides | May 20, 2024 |
| Actinium Pharmaceuticals — Technical Presentation (February 2023) | Technical | 30 slides | Feb 28, 2023 |
| Actinium Pharmaceuticals — Investor Presentation (February 2023) | Investor deck | 42 slides | Feb 21, 2023 |
| Actinium Pharmaceuticals — Technical Presentation (February 2023) | Technical | 42 slides | Feb 18, 2023 |
| Actinium Pharmaceuticals — Technical Presentation (2023) | Technical | 17 slides | 2023 |
All 24 decks
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 90.0K | 0 | 81.0K | 1.03M | 1.14M | 622.0K | 0 | 0 | 0 | 0 |
| Cost of revenue | 811.0K | 790.0K | 699.0K | 900.0K | 447.0K | 420.1K | 50.7K | 55.9K | 77.5K | |
| Gross profit | 90.0K | -811.0K | 81.0K | 1.03M | 620.0K | -447.0K | -420.1K | -50.7K | -55.9K | -77.5K |
| Research and development | 21.1M | 30.0M | 38.7M | 23.1M | 18.0M | 16.1M | 16.6M | 17.1M | 17.7M | 17.8M |
| Selling, general and administrative | 15.2M | 12.1M | 13.3M | 12.0M | 8.08M | 6.31M | 5.52M | 6.73M | 9.15M | 9.27M |
| Operating income | -36.2M | -42.1M | -51.9M | -34.1M | -25.0M | -22.4M | -22.1M | -23.8M | -26.9M | -26.8M |
| Depreciation and amortization | 173.0K | 197.0K | 207.0K | 699.0K | 524.0K | 447.0K | 420.0K | 50.7K | 55.9K | 77.5K |
| EBITDA | -36.1M | -41.9M | -51.7M | -33.4M | -24.4M | -21.9M | -21.7M | -23.8M | -26.9M | -26.8M |
| Interest expense | 1.09M | 190.0K | 0 | 0 | 173.4K | 5.43K | 5.01K | |||
| Income before tax | -33.3M | -38.2M | -48.8M | -33.0M | -24.8M | -22.2M | -21.9M | -23.7M | -26.6M | -24.3M |
| Income tax | 622.1K | -1.09M | -190.0K | -178.0K | -172.0K | 173.4K | -310.0K | 5.01K | ||
| Net income | -33.9M | -38.2M | -48.8M | -33.0M | -24.8M | -22.2M | -21.9M | -23.7M | -26.6M | -24.3M |
| Earnings per share, basic | -1.09 | -1.27 | -1.83 | -1.37 | -1.20 | -1.83 | -4.40 | -0.22 | -0.40 | -0.50 |
| Earnings per share, diluted | -1.09 | -1.27 | -1.83 | -1.37 | -1.20 | -1.83 | -4.40 | -0.22 | -0.40 | -0.50 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 48.0M | 72.9M | 76.7M | 108.9M | 77.8M | 63.6M | 9.25M | 13.7M | 17.4M | 20.5M |
| Short-term investments | 35.0K | |||||||||
| Current assets | 49.4M | 74.5M | 78.3M | 110.9M | 79.7M | 64.9M | 10.1M | 14.3M | 17.8M | 22.4M |
| Property, plant and equipment | 295.0K | 364.0K | 550.0K | 604.0K | 340.0K | 312.0K | 113.0K | 118.8K | 57.4K | 88.5K |
| Goodwill | 100.0K | |||||||||
| Total assets | 51.8M | 76.9M | 81.4M | 114.2M | 80.4M | 66.4M | 11.7M | 14.9M | 18.3M | 22.5M |
| Accounts payable | 7.57M | 7.95M | 10.1M | 5.54M | 4.34M | 4.60M | 5.81M | 4.65M | 4.19M | |
| Current liabilities | 7.97M | 8.15M | 8.49M | 10.6M | 6.84M | 4.77M | 5.34M | 6.06M | 4.67M | 4.52M |
| Long-term debt | 900.0K | |||||||||
| Total debt | 1.69M | 1.57M | 2.11M | 2.58M | 310.0K | 738.0K | 1.43M | 262.6K | ||
| Total liabilities | 43.9M | 44.1M | 45.1M | 47.7M | 6.84M | 5.08M | 6.03M | 6.08M | 4.67M | 4.52M |
| Shareholders' equity | 7.83M | 32.8M | 36.4M | 66.5M | 73.5M | 61.3M | 5.64M | 8.81M | 13.7M | 18.0M |
| Shares outstanding | 31.2M | 31.2M | 27.6M | 25.7M | 22.1M | 17.5M | 5.49M | 115.7M | 80.1M | 55.8M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -24.6M | -33.1M | -47.3M | 8.64M | -20.9M | -21.6M | -21.5M | -20.6M | -21.6M | -20.8M |
| Capital spending | -104.0K | -11.0K | -153.0K | -366.0K | -133.0K | -253.0K | -64.0K | -96.1K | -24.7K | -60.0K |
| Free cash flow | -24.7M | -33.1M | -47.5M | 8.28M | -21.0M | -21.9M | -21.5M | -20.7M | -21.6M | -20.8M |
| Cash from investing | -104.0K | -11.0K | -153.0K | -366.0K | -133.0K | -253.0K | -64.0K | -96.1K | -24.7K | -109.8K |
| Cash from financing | -217.0K | 29.3M | 14.9M | 23.1M | 35.2M | 76.2M | 17.1M | 17.0M | 18.8M | 15.8M |
| Dividends paid | -1.00K | -1.27K | ||||||||
| Share buybacks | -207.0K | 35.3M | 1.00K | 1.27K | 17.0M | 18.8M | 16.0M | |||
| Change in cash | -24.9M | -3.76M | -32.6M | 31.4M | 14.2M | 54.3M | -4.41M | -3.69M | -2.76M | -5.12M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 16, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Oct 16, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 16, 2026 | Insider trade | SEC |
| ARS · Annual report to shareholders | Oct 16, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Oct 16, 2026 | Meeting notice | SEC |
| 8-K · Current report | Oct 15, 2026 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Oct 9, 2026 | Offer document | SEC |
| 3 · Initial statement of ownership | Sep 10, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Sep 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 14, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Aug 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | Jun 18, 2026 | Current report | SEC |
| 8-K · Current report | May 29, 2026 | Current report | SEC |
| 10-Q · Quarterly report | May 8, 2026 | Quarterly report | SEC |
| 10-K · Annual report | Mar 30, 2026 | Annual report | SEC |
| 8-K/A · Current report, amended | Mar 26, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Feb 13, 2026 | Management or board change | SEC |
| 8-K · Current report | Nov 26, 2025 | Management or board change | SEC |
| 10-Q · Quarterly report | Nov 14, 2025 | Quarterly report | SEC |
| ARS · Annual report to shareholders | Nov 5, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Nov 5, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Aug 20, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 8, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 29, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 16, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 9, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 9, 2025 | Current report | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 10-K · Annual report | Mar 31, 2025 | Annual report | SEC |
| 8-K · Current report | Nov 27, 2024 | Management or board change | SEC |
| 10-Q · Quarterly report | Nov 14, 2024 | Quarterly report | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 8, 2024 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Nov 6, 2024 | Annual report | SEC |
| 4 · Change in ownership | Nov 5, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 5, 2024 | Insider trade | SEC |
| 8-K · Current report | Nov 5, 2024 | Management or board change | SEC |
| DEF 14A · Proxy statement | Nov 5, 2024 | Meeting notice | SEC |
| SC 13G · Big-stake notice | Nov 4, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 4, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 5, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Apr 26, 2024 | Quarterly report | SEC |
| S-8 · Registration statement for employee plans | Mar 29, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 29, 2024 | Annual report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2024 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Feb 6, 2024 | Other filings | SEC |
| S-3/A · Registration statement, amended | Feb 2, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Feb 2, 2024 | Other filings | SEC |
| SC 13G · Big-stake notice | Jan 29, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 29, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2023 | Insider trade | SEC |
| 8-K · Current report | Dec 1, 2023 | Management or board change | SEC |
| ARS · Annual report to shareholders | Nov 9, 2023 | Annual report | SEC |
| DEF 14A · Proxy statement | Nov 9, 2023 | Meeting notice | SEC |
| 10-Q · Quarterly report | Nov 2, 2023 | Quarterly report | SEC |
| UPLOAD · Letter from the SEC | Aug 17, 2023 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 14, 2023 | Quarterly report | SEC |
| S-3 · Registration statement | Aug 11, 2023 | Offer document | SEC |
| 10-Q · Quarterly report | May 15, 2023 | Quarterly report | SEC |
| 10-K · Annual report | Mar 31, 2023 | Annual report | SEC |
| 8-K · Current report | Mar 10, 2023 | Current report | SEC |
| 8-K · Current report | Feb 21, 2023 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 6, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Dec 30, 2022 | Management or board change | SEC |
| DEFA14A · Additional proxy material | Dec 9, 2022 | Meeting notice | SEC |
| 8-K · Current report | Dec 9, 2022 | Current report | SEC |
| DEF 14A · Proxy statement | Nov 21, 2022 | Meeting notice | SEC |
| 10-Q · Quarterly report | Nov 14, 2022 | Quarterly report | SEC |
| 8-K · Current report | Oct 31, 2022 | Current report | SEC |
| S-8 · Registration statement for employee plans | Aug 19, 2022 | Offer document | SEC |
| 4 · Change in ownership | Aug 19, 2022 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 12, 2022 | Quarterly report | SEC |
| 4 · Change in ownership | Jul 1, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2022 | Insider trade | SEC |
| 8-K · Current report | Jun 29, 2022 | Material contract | SEC |
| 424B3 · Prospectus | Jun 28, 2022 | Offer document | SEC |
| 10-Q · Quarterly report | May 13, 2022 | Quarterly report | SEC |
| 8-K · Current report | Apr 13, 2022 | Material contract | SEC |
| 10-K · Annual report | Mar 25, 2022 | Annual report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 8, 2022 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2021 | Quarterly report | SEC |
| 8-K · Current report | Nov 9, 2021 | Management or board change | SEC |
| DEFA14A · Additional proxy material | Nov 4, 2021 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Oct 18, 2021 | Meeting notice | SEC |
| 8-K · Current report | Sep 23, 2021 | Management or board change | SEC |
| 4 · Change in ownership | Sep 3, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2021 | Insider trade | SEC |
| 10-Q · Quarterly report | Jul 30, 2021 | Quarterly report | SEC |
| 10-Q · Quarterly report | May 14, 2021 | Quarterly report | SEC |
| 10-K · Annual report | Mar 31, 2021 | Annual report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 12, 2021 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 5, 2021 | Big-stake notice | SEC |
| 8-K · Current report | Nov 20, 2020 | Management or board change | SEC |
| DEFA14A · Additional proxy material | Oct 28, 2020 | Meeting notice | SEC |
| 8-K · Current report | Oct 28, 2020 | Current report | SEC |
| 10-Q · Quarterly report | Oct 23, 2020 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | Oct 7, 2020 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Oct 7, 2020 | Meeting notice | SEC |
| EFFECT · Notice that a registration is effective | Aug 17, 2020 | Other filings | SEC |
| 4 · Change in ownership | Aug 14, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2020 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 14, 2020 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2020 | Current report | SEC |
| 4 · Change in ownership | Aug 14, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2020 | Insider trade | SEC |
| CORRESP · Letter to the SEC | Aug 14, 2020 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 13, 2020 | Other filings | SEC |
| SC 13G · Big-stake notice | Aug 11, 2020 | Big-stake notice | SEC |
| S-3 · Registration statement | Aug 7, 2020 | Offer document | SEC |
| 8-K · Current report | Aug 5, 2020 | Current report | SEC |
| 8-K · Current report | Jul 24, 2020 | Current report | SEC |
| 10-K/A · Annual report, amended | Jul 13, 2020 | Annual report | SEC |
| 10-Q · Quarterly report | Jun 29, 2020 | Quarterly report | SEC |
| 8-K · Current report | Jun 19, 2020 | Current report | SEC |
| 8-K · Current report | Jun 18, 2020 | Material contract | SEC |
| 424B5 · Prospectus | Jun 18, 2020 | Offer document | SEC |
| 8-K · Current report | Jun 16, 2020 | Current report | SEC |
| 424B5 · Prospectus | Jun 16, 2020 | Offer document | SEC |
| 8-K · Current report | Jun 16, 2020 | Current report | SEC |
| 10-K/A · Annual report, amended | Jun 16, 2020 | Annual report | SEC |
| 8-K · Current report | May 15, 2020 | Current report | SEC |
| 10-K · Annual report | May 8, 2020 | Annual report | SEC |
| 8-K · Current report | May 5, 2020 | Current report | SEC |
| 8-K · Current report | May 5, 2020 | Current report | SEC |
| SC 13G · Big-stake notice | May 1, 2020 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Apr 27, 2020 | Big-stake notice | SEC |
| 8-K · Current report | Apr 24, 2020 | Material contract | SEC |
| 424B5 · Prospectus | Apr 22, 2020 | Offer document | SEC |
| 424B5 · Prospectus | Apr 21, 2020 | Offer document | SEC |
| 8-K · Current report | Mar 27, 2020 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2020 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 7, 2020 | Big-stake notice | SEC |
| 8-K · Current report | Dec 19, 2019 | Meeting outcome | SEC |
| 8-K · Current report | Dec 3, 2019 | Current report | SEC |
| DEF 14A · Proxy statement | Nov 25, 2019 | Meeting notice | SEC |
| 8-K · Current report | Nov 25, 2019 | Management or board change | SEC |
| PRE 14A · Preliminary proxy statement | Nov 15, 2019 | Meeting notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2019 | Quarterly report | SEC |
| SC 13G · Big-stake notice | Oct 30, 2019 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 9, 2019 | Quarterly report | SEC |
| 4 · Change in ownership | Jul 16, 2019 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2019 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2019 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2019 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2019 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2019 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2019 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2019 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2019 | Insider trade | SEC |
| 8-K · Current report | Jun 7, 2019 | Current report | SEC |
| 10-Q · Quarterly report | May 10, 2019 | Quarterly report | SEC |
| S-8 · Registration statement for employee plans | May 10, 2019 | Offer document | SEC |
| 8-K · Current report | Apr 18, 2019 | Material contract | SEC |
| 424B5 · Prospectus | Apr 18, 2019 | Offer document | SEC |
| SC 13G · Big-stake notice | Apr 18, 2019 | Big-stake notice | SEC |
| 424B5 · Prospectus | Apr 17, 2019 | Offer document | SEC |
| 10-K · Annual report | Mar 15, 2019 | Annual report | SEC |
| 8-K · Current report | Mar 12, 2019 | Material contract | SEC |
| 4 · Change in ownership | Mar 7, 2019 | Insider trade | SEC |
| 4 · Change in ownership | Feb 21, 2019 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2019 | Big-stake notice | SEC |
| 424B5 · Prospectus | Dec 28, 2018 | Offer document | SEC |
| 8-K · Current report | Dec 28, 2018 | Material contract | SEC |
| 8-K · Current report | Dec 26, 2018 | Management or board change | SEC |
| 8-K · Current report | Dec 21, 2018 | Meeting outcome | SEC |
| 4 · Change in ownership | Dec 10, 2018 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2018 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2018 | Insider trade | SEC |
| DEF 14A · Proxy statement | Nov 16, 2018 | Meeting notice | SEC |
| 10-Q · Quarterly report | Nov 9, 2018 | Quarterly report | SEC |
This page holds 200 of 512 filings. Open Filings
Cap table
Built by 6ix from Actinium Pharmaceuticals, Inc. (Delaware)’s releases · as of Nov 13, 2026
- Common shares
- 31,441,436
- Fully diluted
- 31,441,436
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 31,441,436 | Nov 13, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 13, 2026 | 31,441,436 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Rosemary Mazanet Other companies: Kairos Pharma, Ltd. (Director · Sep 16, 2024 – Sep 16, 2024 · Past); SELLAS Life Sciences Group, Inc. (Chief Medical Officer · Feb 1, 2012 – Jan 29, 2013 · Past); Abeona Therapeutics Inc. (Director · Jan 4, 2007 – Jan 4, 2007 · Past); Aksys Ltd (Director · Aug 9, 2006 – Oct 24, 2006 · Past); Oncternal Therapeutics Inc (Director · Jan 1, 2006 – Jun 20, 2024 · Past) | Director · Dec 28, 2012 – May 15, 2013 · Past |
| Richard I. Steinhart Other companies: BioXcel Therapeutics, Inc. (Senior Vice President and Chief Financial Officer · Since at least Mar 7, 2018); Atossa Therapeutics, Inc. (Director · Since at least Mar 1, 2014); MELA Sciences Inc (Chief Financial Officer · May 14, 2010 – Aug 5, 2013 · Past); TG Therapeutics, Inc. (Director · Mar 25, 2008 – Mar 3, 2010 · Past) | Director · Since at least Nov 8, 2013 |
| Anil Kapur Other companies: Nurix Therapeutics, Inc. (Director · Since at least Oct 15, 2024); Verastem, Inc. (Member, Audit Committee; Member, Compensation Committee; Member, Commercialization Committee · Since at least Oct 20, 2022); Geron Corporation (EVP, Corp Strategy & CCO · Dec 2, 2019 – Jun 10, 2024 · Past) | Chief Commercial Officer · Feb 6, 2018 – Jul 12, 2019 · Past |
| June Almenoff Other companies: Tenax Therapeutics, Inc. (Director · Since at least Dec 10, 2024); Avalo Therapeutics, Inc. (Director · Since at least Dec 20, 2023) | Director · Since at least Nov 1, 2024 |
| C. David Nicholson Other companies: Adverum Biotechnologies Inc (Director · Since at least Nov 3, 2023) | Director · Since at least Dec 28, 2023 |
| Dragan Cicic Other companies: SELLAS Life Sciences Group, Inc. (Senior Vice President, Chief Development Officer · Since at least Jun 20, 2024) | Chief Technology Officer · Dec 28, 2012 – Mar 14, 2017 · Past |
| Kaushik J Dave Other companies: Antares Pharma Inc (Executive Vice President · May 6, 2013 – Jun 3, 2013 · Past) | CEO and Interim CFO, Director · Sep 16, 2013 – Mar 14, 2017 · Past |
| Mark Stanley Berger Other companies: Genprex, Inc. (Chief Medical Officer · Since at least Sep 27, 2021) | Chief Medical Officer · Mar 16, 2017 – Sep 1, 2021 · Past |
| Steve O'Loughlin Other companies: CNS Pharmaceuticals, Inc. (Chief Financial Officer · Since at least Mar 2, 2026) | Chief Financial Officer · Sep 1, 2021 – Mar 31, 2025 · Past |
| Adeela Kamal | Chief Scientific Officer · Since at least Sep 3, 2026 |
All 24 people
| Person | Seat |
|---|---|
| Ajit Shetty | Director · Since at least Mar 28, 2017 |
| Enza Guagenti | Chief Financial Officer · Dec 28, 2012 – Dec 28, 2012 · Past |
| Gary Siegel | Vice President, Controller · Since at least Nov 5, 2026 |
| Jeffrey W. Chell | Director · Since at least Apr 27, 2018 |
| Julie Gibson | Vice President, Portfolio and Clinical Operations · Since at least Nov 5, 2026 |
| Matt David | Chief Financial Officer · Since at least Oct 15, 2026 |
| Matthew T David | Chief Financial Officer · Since at least Oct 14, 2026 |
| Monideepa Roy | Senior Vice President, Corporate Development – R&D · Since at least Apr 22, 2026 |
| Paul Diamond | Vice President, Legal and Intellectual Property Counsel · Since at least Nov 5, 2026 |
| Richard l. Steinhart | Director · Since at least Sep 4, 2026 |
| Ryan Chu | Vice President, Finance and Investor Relations · Since at least Nov 5, 2026 |
| Sandesh Seth | Chief Executive Officer and Chairman of the Board · Since at least Mar 31, 2025 |
| Sean Maenpaa | Senior Vice President, Business Development · Since Oct 12, 2026 |
| Steffen Heeger | Chief Medical Officer · Since at least Jun 1, 2026 |
Log in to ask 6ix AI your own questions about Actinium Pharmaceuticals, Inc. (Delaware).